Thirteen patients (45%) were male and 16 (55%) were female (55%), with a mean age of 25.2 years (range 1-66 years) at the initial surgery. Thirteen patients were younger than 18 years, and two were younger than 3 years. In seven cases (24%) the lesion was located in the fourth ventricle below the tentorium, and in 22 cases (76%) the lesion was supratentorial, that is, three (10%) in the lateral ventricle, two (7%) in the third ventricle, and 17 (59%) in the brain parenchyma.
Hematoxylin and eosin-stained sections obtained in all patients were examined. Tumors were classified as classic ependymomas (Grade II) and anaplastic ependymomas (Grade III) according to the WHO classification system. 1 A review of the tissues was performed by an investigator (J.A.T.) who was unaware of the patient outcomes. Analysis of the results showed that 18 patients harbored a low-grade tumor (ependymoma), and 11 a high-grade tumor (anaplastic ependymoma). In the subgroup of patients whose age was less than 3 years, one patient had a low-grade tumor and the other had a high-grade tumor.
The extent of resection was determined based on a review of postoperative CT scanning and/or MR imaging studies and was classified as total (100%), subtotal (Ͼ 90%), or partial (Ͻ 50%). Macroscopically gross-total (total/subtotal) resection was performed in 26 patients (90%), and partial resection in three patients (10%). In one patient, a second surgery was performed after the initial partial resection of a Grade III ependymoma, thus ultimately resulting in total resection. Among patients harboring a Grade II ependymoma, gross-total resection was performed in 17 and partial resection in one. In patients with a Grade III ependymoma, gross-total resection was performed in nine and partial in two.
Twenty-four (83%) of 29 patients received external beam radiation as a postoperative therapy. All patients with a Grade III lesion and those who demonstrated residual tumor on postoperative imaging underwent radiotherapy. Five of 18 patients with Grade II lesions did not receive radiotherapy postoperatively because the tumor had been totally resected. Two patients younger than 3 years at the time of initial surgery received conventional radiotherapy, although, in Japan, the current standard regimen in this subgroup of patients is chemotherapy to defer radiotherapy. The primary lesion received 45.4 to 61.2 Gy (median 50.6 Gy) radiation. In the 24 patients who underwent radiotherapeutic treatment, radiation was applied to the local field only in seven cases (median 50.4 Gy, range 50-61.2 Gy). Whole-brain radiation (median 50 Gy, range 30-60 Gy) was administered in 11 patients, and whole-neuraxis radiation was applied in five, one of whom had CSF dissemination at diagnosis (45 Gy) and four of whom prophylactically received wholespine radiation (median 27.4 Gy, range 26-30.4 Gy). No information was available regarding either radiation dose or field in one patient, who was therefore excluded from prognostic analysis.
Nine patients received chemotherapy as part of their initial treatment, usually cisplatin, endoxane, vincristine, or (1-4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitrosourea.
Surveillance neuroimaging was performed using MR imaging at varying time intervals. Disease progression after treatment was based on the recurrence of symptoms and/or the presence of a tumor on postoperative MR images. The median follow-up time was 92 months (15-302 months). Estimates of OS and PFS were calculated using the Kaplan-Meier method. Both OS and PFS were calculated from the time of initial diagnosis to death by any cause and to recurrence, respectively. The log-rank test was used to compare survivals according to patient, tumor, and treatment characteristics. The risk of CSF dissemination was also calculated using the log-rank test.
The following variables were analyzed for correlation with patient outcome: sex, age (Ͻ 18 years compared with Ն 18 years), tumor location (infratentorial or supratentorial), extent of resection (gross total compared with partial), WHO-based tumor histological grades of malignancy (Grade II compared with Grade III), addition of chemotherapy, the fields of radiotherapy (local, whole-brain, and whole-neuraxis radiation), and pattern of tumor recurrence (no recurrence, local recurrence without CSF dissemination, CSF dissemination).
Results

Prognostic Factors
The 5-and 10-year OS rates in all 29 patients were 81 and 59%, respectively. The 5-and 10-year PFS rates were 51 and 36%, respectively. Five-year OS was 80 and 75% in patients treated in the whole-craniospinal axis or wholebrain field and the localized field, respectively. Five-year PFS was 46 and 50% in patients treated in the whole-craniospinal axis or whole-brain field and the localized field, respectively. The differences in both OS and PFS were not statistically significant (p = 0.1818 and 0.429, respectively). Overall survival and PFS rates according to various possible prognostic factors are summarized in Tables 2 and 3 .
On univariate analysis, the significant prognostic factors for both OS and PFS were extent of resection and tumor histological grade (Figs. 1 and 2). The 5-year OS rates of Grade II and Grade III ependymoma were 100 and 55%, respectively. The 5-year PFS rates of Grade II and Grade III ependymoma were 64 and 27%, respectively. Both the OS and PFS were significantly better in patients who had undergone gross-total tumor resection compared with those in patients who had undergone partial resection (p = 0.002 for OS and p = 0.04 for PFS, respectively). Paradoxically, PFS was negatively associated with the use of chemotherapy postoperatively.
Consequentially, patients with Grade II ependymomas who had undergone gross-total resection had the best prognosis. Ten of 11 patients in this group remain alive a median of 112 months (24-302 months) after diagnosis; only one of 11 patients experienced repeated local relapses and eventually suffered CSF dissemination and died 78 months after disease diagnosis. In this group, all five patients who did not undergo radiotherapy remain alive a median of 58 months (24-194 months) after diagnosis.
The OS curve according to the tumor recurrence pattern is shown in Fig. 3 . Dissemination was the most significant prognostic factor of OS. At the time of the follow-up review, five of six patients with disseminated disease had died compared with seven of 23 patients without dissemination who had died (p = 0.0001). The only survivor despite CSF dissemination had actually demonstrated dissemination on the initial diagnosis. In this patient the tumor at the primary site was totally resected, and craniospinal axis radiation and chemotherapy (carboplatin and etoposide) were added postoperatively without progression for 71 months. The median survival time after CSF dissemination in these five patients was 17 months (range 4-34 months).
Patterns of Recurrence
Fourteen of 29 patients relapsed a median of 13.5 months (6-120 months) after the start of treatment, within 5 years in 12 (86%). Twelve (86%) of these 14 recurrences initially occurred at the primary tumor site. All six relapses of Grade II and six of eight relapses of Grade III ependymoma initially occurred locally. In two patients with Grade III ependymoma, the tumor recurred at a distant site without local relapse.
In patients with Grade II ependymoma, CSF dissemination eventually occurred in only one patient (5.6%) following three local relapses. On the other hand, in patients with Grade III ependymoma, CSF dissemination occurred in five (45%)-one at initial diagnosis, two after local relapses, and two without local recurrence.
Risk Factors for CSF Dissemination
Risk factors for CSF dissemination were analyzed (Table TABLE 2 4), except in the patient with CSF dissemination on initial diagnosis who was excluded from this analysis. As mentioned previously, 21, 23 Grade III tumor and partial resection were significant risk factors for CSF dissemination. Location and presence of local recurrence did not affect the occurrence of CSF dissemination. Neither whole-brain radiation nor whole-spine radiation affected the development of CSF dissemination.
Discussion
Surgical Treatment
The treatment of choice for intracranial ependymomas remains resection, as extensive as possible, which prolongs OS and decreases the rate of CSF dissemination. 1, 4, 7, 11, 15, 16, [19] [20] [21] [22] 25, 28 In our series, the extent of tumor resection was the major prognostic factor in terms of survival, recurrence, and dissemination. Thus, we recommend performing a second surgery in patients who have undergone less than near-total resection initially. Note, however, that some authors 8, 10, 22, 27 have found no correlation between extent of resection and prognosis. In the present series the difference in survival between the total and subtotal resection groups did not reach statistical significance. This finding may reflect the presence of microscopic residual tumors that could have been overlooked by the surgeon or on postoperative imaging, partially because only CT scanning was postoperatively performed early in the series. All patients who experienced recurrence despite complete tumor resection underwent CT scanning but not MR imaging postoperatively. Nevertheless, Pollack, et al., 20 reported that patients with negative findings on postoperative Gd-enhanced MR imaging studies ultimately experienced progressive disease. Although MR imaging is more reliable than CT scanning, the findings of Pollack and colleagues may have resulted from limitations of current imaging technology in detecting small foci of residual tumor.
Histological Grade
In the present series, tumor grade had prognostic value for OS and PFS. Authors of many studies 4, 7, 8, 12, 15, 19, 21, 23 have observed a more favorable prognosis for Grade II ependymomas, with histological characteristics being an independent predictor of survival. Not all authors admit the prognostic value of histological grade, however. 5, 10, 20, 22 There are several reasons why such a discrepancy exists. First, there are difficulties in and disagreements about the classification of ependymoma. In one study 22 there was a 67% discrepancy rate between individual institutional readings and a central pathological review. In the present series we used the WHO classification system revised in 2000. Second, in the older studies, ependymoblastomas were often confused with high-grade or malignant ependymomas. Ep- endymoblastomas are now properly classified with primitive neuroectodermal tumors. 9 Third, the limited size of series reported on and the bias related to a selected population of patients in large institutions' reports may explain discrepancies.
Adjuvant Therapy
The theoretical justification for whole-brain or craniospinal radiation is the potential risk of tumor seeding through CSF patterns. In our data, however, the use of craniospinal or whole-brain radiation had no impact on OS or PFS. Authors of previous reports, 5, 11, 18 also found no benefit of craniospinal or whole-brain radiation on prognosis. Considering the fact that intracranial ependymoma relapse occurs predominantly at the primary tumor site, 10, 11, 15, [17] [18] [19] 22, 23, 27 radiotherapy should be focused on local control, especially for Grade II ependymoma.
Benefits of postoperative radiation are controversial for Grade II ependymomas. 1, 4, 16 When low-grade ependymomas are completely resected, the prognosis is fairly good without radiation. Thus, radiotherapy is indicated in cases of malignant ependymoma and partially resectable primary or recurrent benign ependymoma.
In the present series the use of chemotherapy as a postoperative treatment was associated with poor outcome. Although this result is likely to be biased by the fact that chemotherapy was applied mainly to anaplastic ependymoma or in the presence of residual tumor, the addition of chemotherapy should be reserved for use in children to defer radiotherapy 1, 3 or as a salvage therapy for recurrent tumors. 
Cerebrospinal Fluid Dissemination
The development of CSF dissemination was fatal in most cases. Five patients died within 3 years after the diagnosis of CSF dissemination. In the only survivor (Case 23) with CSF dissemination, the dissemination was diagnosed at the start of initial treatment. Early detection and the immediate administration of postoperative craniospinal radiation combined with chemotherapy might cure CSF dissemination of ependymoma.
Histological grade had a great impact on the future risk of CSF dissemination in our series. In patients with Grade II tumors, the CSF dissemination rate was 5.6% compared with 36% in patients with Grade III tumors (p = 0.0034). In addition, CSF dissemination from a Grade II tumor occurred only after three local relapses (Case 3). These results were similar to those reported by Schild and colleagues. 23 Rezai, et al., 21 also reported that younger patients who had undergone subtotal resections or harbored high-grade tumors had a substantial risk for suffering disseminated disease during their clinical course. Thus, it is very important to diagnose the histological characteristic of ependymomas accurately to predict the future risk of CSF dissemination, which is almost always fatal.
Postoperative Surveillance
Recently, the value of postoperative surveillance imaging in the treatment of patients with brain tumors has been emphasized. 6, 13, 14, 24, 26 Earlier detection of asymptomatic recurrence can improve outcome in patients with ependymoma. 24 In our series, 12 (85.7%) of 14 relapses occurred within 5 years after diagnosis. Thus, careful follow up, including spinal MR imaging, will be necessary within this period. Highrisk patients-those with Grade III and residual tumorin particular should be followed up with a heightened suspicion of dissemination. Furthermore, strict surveillance with periodic contrast-enhanced MR imaging is mandatory at least once every 3 months even after imaging-proven complete remission.
Conclusions
In summary, we noted rare disease entities of intracranial ependymoma. Univariate analysis revealed that the extent of resection and tumor grade were significant prognostic factors with respect to OS, PFS, and future risk of CSF dissemination. Tumor relapse predominantly occurred at the primary tumor site. Radiotherapy should be focused on local control. Two major limitations of our study include the facts that it is retrospective and that it consists of a small number of patients. National or, better yet, international cooperative trials are necessary to draw some definitive conclusions about ependymomas.
